Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis

Elliot B. Tapper, James B. Henderson, Neehar D. Parikh, George N. Ioannou, Anna S. Lok – 6 September 2019 – Hepatic encephalopathy (HE) is a devastating complication of cirrhosis. Data are limited regarding the incidence of and risk factors for HE among contemporary patients in the context of the shifting epidemiology of cirrhosis. We examined a 20% random sample of U.S. Medicare enrollees with cirrhosis and Part D prescription coverage from 2008 to 2014. We modelled incident HE using demographic, clinical, and pharmacologic data.

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists

Kathy M. Nilles, Stephen H. Caldwell, Steven L. Flamm – 4 September 2019 – Thrombocytopenia is common in patients with advanced liver disease. These patients frequently require invasive diagnostic or therapeutic procedures in the setting of thrombocytopenia. A common platelet goal before such procedures is ≥50,000/μL, but target levels vary by provider and the procedure. Platelet transfusion has disadvantages, including safety and cost.

R‐spondin 2 Drives Liver Tumor Development in a Yes‐Associated Protein‐Dependent Manner

Caitlin B. Conboy, Germán L. Vélez‐Reyes, Barbara R. Tschida, Hsiangyu Hu, Gabriel Kaufmann, Nicholas Koes, Bryant Keller, Clara Alsinet, Helena Cornellà, Roser Pinyol, Juan E. Abrahante, Nuri A. Temiz, Michael A. Linden, Khalid Amin, Timothy P. Kuka, Vincent W. Keng, Josep M. Llovet, Timothy K. Starr, David A. Largaespada – 3 September 2019 – Each year, more than 25,000 people succumb to liver cancer in the United States, and this neoplasm represents the second cause of cancer‐related death globally.

Subscribe to